Usha Arunachalam
Profile
Usha Arunachalam is Vice President of Business Development for Five Prime Therapeutics, Inc. Prior to joining FivePrime, she was Vice President of Business Development at Intrabiotics and a Member of an Executive Team.
Before joining Intrabiotics, Dr. Arunachalam was a Senior Director of Business Development at Kosan Biosciences.
She received her PhD in Biochemistry from the Indian Institute of Science and a pre-doctoral fellowship from the University of Michigan.
Dr. Arunachalam received an MBA from the Anderson School of Management, University of California, Los Angeles.
Former positions of Usha Arunachalam
| Companies | Position | End |
|---|---|---|
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Corporate Officer/Principal | 21/01/2007 |
Kosan Biosciences, Inc.
 Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Usha Arunachalam
| University of California, Los Angeles | Masters Business Admin |
| Indian Institute of Science | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 3 |
|---|---|
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Kosan Biosciences, Inc.
Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Usha Arunachalam
